Navigation Links
Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
Date:6/2/2009

EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the appointment of Klaus Kohl, Ph.D., as Senior Vice President and Chief Technical Officer. Dr. Kohl brings to Bionovo over 20 years of experience in product development and manufacturing. Dr. Kohl will be responsible for manufacturing, quality assurance, and regulatory compliance.

"We are very excited to add Dr. Kohl to our management team," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "We believe Dr. Kohl's extensive background in the pharmaceutical industry will prove invaluable to Bionovo's current efforts. Klaus' two decades of experience and broad knowledge will optimize our organization to meet with partnering and commercialization standards."

Dr. Kohl's most recent position was as Vice President of Program Management, CMC and Regulatory Affairs at Novo Nordisk Delivery Technologies, where he was responsible for the development of an inhaled insulin drug/device combination product. Prior to Novo Nordisk, Dr. Kohl served as Senior Vice President, Quality and Technical Director at Aradigm Corporation, a specialty pharmaceutical development company focused on respiratory disease management.

From 1985 to 2001, Dr. Kohl worked for Bayer Corporation, where he held various executive positions in quality assurance and drug product development. Before Bayer, Dr. Kohl was engaged in basic research for more than seven years at the Juelich Research Center in Germany, and the Max Planck Institute in Dortmund, Germany.

Dr. Kohl holds an undergraduate degree in Mathematics and Physics from the University of Marburg, Germany, and a master's degree in Experimental Physics and Ph.D. in Biophysics from the University of Aachen, Germany.

Dr. Kohl states, "I feel I am joining
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
2. Bionovo Announces 2008 Highlights and Year-End Financial Results
3. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
4. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
5. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
6. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
7. Bionovo to Present at the Piper Jaffray Healthcare Conference
8. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Reports Third Quarter 2008 Financial Results
10. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... FRANCISCO, Calif. , May 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... announced today the completion of its merger with ... In conjunction with the closing of the merger, ... a combination of new investors and all current ...
(Date:5/4/2015)... BOSTON , May 4, 2015 ... development of novel therapies for neurological and neuropsychiatric ... has initiated dosing of Alzheimer,s patients in a ... candidate, GC021109, a compound developed as a potential ... disease is innovative in that it both promotes ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), ... the appointment of Dr. Roger J Garceau, to ... biotech companies in matters including corporate development and ... and adds significant regulatory expertise as Fluorinov transitions ... brings 30 years of pharmaceutical development experience to ...
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
Breaking Biology Technology:Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... New Launches Should Contribute Significantly in Second Half, ... PRX ) today announced results for the,second quarter ended ... For the second quarter ended June 28, 2008, Par ... $20.1 million, or $0.60 per diluted,share. This is compared with ...
... ITMN ) today announced that Daniel G. Welch, ... Canaccord Adams 28th Annual,Global Growth Conference in Boston on ... access a live audio webcast of the presentation, investors ... relations page of InterMune,s,corporate website at http://www.intermune.com . ...
... YORK, Aug. 7 Microbes, Inc. today announced that ... all of its outstanding,Class B Common Stock Purchase Warrants, ... 2 until 12:00 midnight, New York City time, on,Friday, ... at 12:00,midnight, New York City time, on August 7, ...
Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a key source of water for millions of people in ... climate changes as expected and future water usage is not ... of Oceanography, UC San Diego. Without Lake ... no buffer to sustain the population of the Southwest through ...
... Feb. 11 Most fashion consumers consider,custom-made jeans ... lottery,winners. But Intellifit, a leader in proprietary apparel ... perception., This week, the company will begin ... company retail store outside of Philadelphia. Using Intellifit,technology, ...
... the Moores Cancer Center at University of California, San Diego ... were treated with a gene therapy protocol began making antibodies ... be published on line the week of February 11-15 in ... of Science. Researchers led by Thomas J. Kipps, M.D., ...
Cached Biology News:Lake Mead could be dry by 2021 2Lake Mead could be dry by 2021 3Intellifit(R) Offers Custom-Made Jeans with a High-Tech Twist 2Gene therapy protocol at UCSD activates immune system in patients with leukemia 2